EUVIMEDOpdag EUVIMED
Crossref

New oral anticoagulants and related anxiety symptoms

Y. W. Francis Lam

The Brown University Psychopharmacology Update · 2026-09 · 37 (9) · 2-2

DOI: 10.1002/pu.31486 ↗

At a glance

Journal article in The Brown University Psychopharmacology Update, published online on 2026-08-03. Written by Y. W. Francis Lam. 1 references.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Newer oral anticoagulants (NOACs), now most commonly referred to as direct oral anticoagulants (DOACs), have replaced warfarin in preventing clot formation and minimizing the risk of stroke in patients with atrial fibrillation. Unlike warfarin, which exerts its anticoagulant effect indirectly by inhibiting vitamin K metabolism, DOACs have a direct anticoagulant effect via inhibition of specific coagulation factors such as activated factor II (Iia, thrombin) or activated factor X (Xa). Not only are DOACs highly effective and convenient for patients, they also do not entail the close monitoring of pharmacologic effect required with warfarin. As a result, their use is included in clinical guidelines and favored by clinicians as first‐line treatment.

Cite

APA

Lam, Y. W. F. (2026). New oral anticoagulants and related anxiety symptoms. The Brown University Psychopharmacology Update, 37(9), 2-2. https://doi.org/10.1002/pu.31486

Vancouver

Lam YWF. New oral anticoagulants and related anxiety symptoms. The Brown University Psychopharmacology Update. 2026;37(9):2-2. doi:10.1002/pu.31486

BibTeX
@article{Lam2026,
  author = {Lam, Y. W. Francis},
  title = {New oral anticoagulants and related anxiety symptoms},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {9},
  pages = {2--2},
  doi = {10.1002/pu.31486}
}
Start for free →